| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Ki: 385 μM (ADA)[1]
L-Adenosine targets adenosine deaminase (ADA), exhibiting weak inhibitory activity with a Ki of 385 µM. It also binds to adenosine receptors (A1, A2A, A2B, and A3). The compound's primary value lies in its metabolic stability, making it a useful tool for studying adenosine-related pathways without being rapidly degraded by ADA. |
|---|---|
| ln Vitro |
Rat brain adenosine deaminase (ADA) activity is weakly inhibited by L-adenosine (10–10,000 μM), with a Ki value of 385 μM[1].
In vitro, L-Adenosine (10-10,000 µM) weakly inhibits rat brain adenosine deaminase (ADA) activity with a Ki value of 385 µM. This weak inhibition allows the compound to be used as a probe for adenosine uptake studies. Its binding to adenosine receptors modulates various cellular signaling pathways. |
| ln Vivo |
In vivo, L-Adenosine is expected to have therapeutic implications in conditions such as epilepsy, ischemia, pain, and neurodegenerative diseases. Its metabolic stability suggests a longer duration of action compared to natural adenosine. However, detailed in vivo efficacy data are limited and require further investigation.
|
| Enzyme Assay |
Cell-free assays for L-Adenosine include adenosine deaminase (ADA) activity assays, where the enzyme's ability to deaminate adenosine to inosine is measured spectrophotometrically at 265 nm. The Ki value of L-Adenosine for ADA inhibition is determined from enzyme kinetics studies using varying substrate and inhibitor concentrations. Receptor binding assays using radiolabeled ligands can assess affinity for adenosine receptor subtypes.
|
| Cell Assay |
In vitro cellular assays for L-Adenosine involve treating cultured cells with the compound and measuring adenosine uptake and accumulation using radiolabeled or fluorescent adenosine analogs. The compound's effects on cell signaling pathways downstream of adenosine receptors are assessed by measuring cAMP levels or other second messengers.
|
| Animal Protocol |
In vivo animal studies for L-Adenosine would typically involve administration in rodent models of ischemia, epilepsy, or pain. The compound's metabolic stability makes it suitable for studying adenosine-mediated effects without rapid degradation. Endpoints include behavioral assessments, electrophysiological recordings, and biochemical measurements of adenosine levels and receptor signaling.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of L-Adenosine include metabolic stability due to its resistance to adenosine deaminase degradation. This stability results in a longer half-life compared to natural D-adenosine. The compound is expected to be distributed throughout the body and can cross the blood-brain barrier. Further detailed PK studies are needed to characterize its absorption and elimination.
|
| Toxicity/Toxicokinetics |
Available toxicological data for L-Adenosine are limited. As a naturally occurring nucleoside analogue, it is expected to have a manageable safety profile at research doses. Standard toxicity assessments would be required for therapeutic development. The compound's weak ADA inhibition suggests a low risk of adenosine-related toxicity.
|
| References | |
| Additional Infomation |
L-Adenosine is a research compound with no clinical approvals. Its primary applications are as a probe for studying adenosine uptake and accumulation and as a tool for investigating adenosine receptor signaling. Therapeutic derivatives are being considered for anticonvulsant, anti-ischemic, analgesic, and neuroprotective applications.
|
| Molecular Formula |
C10H13N5O4
|
|---|---|
| Molecular Weight |
267.24
|
| Exact Mass |
267.097
|
| CAS # |
3080-29-3
|
| PubChem CID |
448374
|
| Appearance |
White to off-white solid powder
|
| Density |
2.085 g/cm3
|
| Boiling Point |
676.271ºC at 760 mmHg
|
| Melting Point |
257.0-257.5ºC (0.4 H2O)
|
| Flash Point |
362.796ºC
|
| LogP |
-1.1
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
335
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC(=C2C(=N1)N(C=N2)[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)N
|
| InChi Key |
OIRDTQYFTABQOQ-DEGSGYPDSA-N
|
| InChi Code |
InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m0/s1
|
| Chemical Name |
(2S,3S,4R,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7420 mL | 18.7098 mL | 37.4195 mL | |
| 5 mM | 0.7484 mL | 3.7420 mL | 7.4839 mL | |
| 10 mM | 0.3742 mL | 1.8710 mL | 3.7420 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
